https://www.selleckchem.com/pr....oducts/Nanchangmycin
The alpha-emitter 225Ac (t1/2 = 9.92 d) is currently under development for targeted alpha-particle therapy of cancer, and accelerator production of 225Ac via proton irradiation of thorium targets requires robust separations of 225Ac from chemically similar fission product lanthanides. Additionally, the lanthanide elements represent critical components in modern technologies, and radiolanthanides such as 140Nd (t1/2 = 3.37 d) also have potential application in the field of nuclear medicine. The ionic liquid, 1-butyl-3-methylimidazo
Curtir
Comentario
Compartilhar
